• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study
Conclusion: In real practice, ticagrelor swi tching among patients with STE-ACS post streptokinase therapy did not differ regarding safety outcomes and composite of efficacy outcomes compared with clopidogrel.
Source: PLoS One - August 4, 2023 Category: Biomedical Science Authors: Phornpaka Ueapornpanith Source Type: research

Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention
ConclusionsCombination of low-dose prasugrel and DOAC was associated with lower incidence of MI, ischemic stroke, and blood transfusion. Low-dose prasugrel may be feasible as part of triple therapy in patients undergoing PCI.
Source: PLoS One - July 28, 2022 Category: Biomedical Science Authors: Hideki Kitahara Source Type: research

Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk
CONCLUSIONS: The bleeding risk of ticagrelor was attenuated in Korean patients with AMI without HBR. Appropriate patient selection could reduce in-hospital bleeding complications associated with ticagrelor in Korean patients with AMI who underwent successful PCI.PMID:34725976 | DOI:10.3346/jkms.2021.36.e268
Source: Journal of Korean Medical Science - November 2, 2021 Category: Biomedical Science Authors: Keun-Ho Park Myung Ho Jeong Hyun Kuk Kim Young-Jae Ki Sung Soo Kim Dong-Hyun Choi Young-Youp Koh Youngkeun Ahn Hyo-Soo Kim Hyeon-Cheol Gwon Seung-Woon Rha Jin-Yong Hwang KAMIR-NIH registry investigators Source Type: research

Impact of genetic variants on clinical outcome after percutaneous coronary intervention in elderly patients
In conclusion, poor metabolizers of CYP2C19 and TT groups of P2Y12 G52T may be significant predictors of poor clinical outcomes in elderly patients.PMID:33707344 | DOI:10.18632/aging.202799
Source: Aging - March 12, 2021 Category: Biomedical Science Authors: Jung-Joon Cha Jae Hyoung Park Hyung Joon Joo Soon Jun Hong Tae Hoon Ahn Byeong-Keuk Kim WonYong Shin Sung Gyun Ahn JungHan Yoon Yong Hoon Kim Yun-Hyeong Cho Woong Chol Kang Weon Kim Young-Hyo Lim Hyeon Cheol Gwon Woong Gil Choi Do-Sun Lim Source Type: research

Efficacy and safety of an antithrombotic regimen for atrial fibrillation patients with acute coronary syndrome or those undergoing percutaneous coronary intervention: a meta-analysis.
This study evaluated the benefit of dual therapy in reducing ischemic events in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI). We searched PubMed, Cochrane Library, and ClinicalTrials.gov for randomized controlled trials (RCTs) comparing dual and triple therapies (oral anticoagulation plus aspirin and P2Y12 inhibitor) for AF patients with ACS or those undergoing PCI. The composite primary outcome included all-cause death, myocardial infarction (MI), stent thrombosis (ST), or stroke. Relative risk (RR) and the corresponding 95% confiden...
Source: Aging - June 30, 2020 Category: Biomedical Science Authors: Guo W, Chen X, Hao Y, Liu Q, Peng C, Zhao L, Feng Z, Wang X, Ruan H, Li L Tags: Aging (Albany NY) Source Type: research